These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 28739563)

  • 1. Efficacy of new low-dose oral anticoagulants in recalcitrant livedoid vasculopathy.
    Furukawa F; Mizawa M; Makino T; Shimizu T
    BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28739563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Livedoid vasculopathy - current aspects of diagnosis and treatment of cutaneous infarction.
    Kerk N; Goerge T
    J Dtsch Dermatol Ges; 2013 May; 11(5):407-10. PubMed ID: 23437985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case of livedoid vasculopathy with peripheral neuropathy successfully treated with low-dose warfarin.
    Osada S; Kimura Y; Kawana S
    J Dermatol; 2010 Jan; 37(1):98-101. PubMed ID: 20175830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Livedoid vasculopathy - a thrombotic disease.
    Kerk N; Goerge T
    Vasa; 2013 Sep; 42(5):317-22. PubMed ID: 23989066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathy.
    Kerk N; Drabik A; Luger TA; Schneider SW; Goerge T
    Br J Dermatol; 2013 Apr; 168(4):898-9. PubMed ID: 23106384
    [No Abstract]   [Full Text] [Related]  

  • 6. Negative Results, Positive Outcome: A Case of Primary Livedoid Vasculopathy With an Elusive Laboratory Workup.
    Al-Obaidi AD; Sabeeh SK; Mohammed MJ; Othman A; Algburi YA; Hashim HT; Alhatemi AQM; Al Hilali Z; Al-Attabi BRT; Al-Awad A
    J Investig Med High Impact Case Rep; 2024; 12():23247096241266090. PubMed ID: 39068597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Livedoid vasculopathy. Pathogenesis, diagnosis and treatment of cutaneous infarction].
    Goerge T
    Hautarzt; 2011 Aug; 62(8):627-34; quiz 635. PubMed ID: 21786003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dabigatran in the management of livedoid vasculopathy.
    Sawada T; Suehiro M
    Clin Exp Dermatol; 2017 Mar; 42(2):237-239. PubMed ID: 28052437
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevention of recurrent ulceration of livedoid vasculopathy with long-term apixaban monotherapy.
    Osada SI; Ishikawa N; Hasunuma N; Manabe M
    J Dermatol; 2019 Apr; 46(4):e142-e143. PubMed ID: 30156315
    [No Abstract]   [Full Text] [Related]  

  • 10. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial.
    Weishaupt C; Strölin A; Kahle B; Kreuter A; Schneider SW; Gerss J; Eveslage M; Drabik A; Goerge T
    Lancet Haematol; 2016 Feb; 3(2):e72-9. PubMed ID: 26853646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Livedoid Vasculopathy Presenting in a Patient With Sickle Cell Disease.
    Reagin H; Marks E; Weis S; Susa J
    Am J Dermatopathol; 2018 Sep; 40(9):682-685. PubMed ID: 29533274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysis.
    Weishaupt C; Strölin A; Kahle B; Kreuter A; Schneider SW; Gerss J; Eveslage M; Drabik A; Goerge T
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1784-1791. PubMed ID: 31009111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What caused this painful skin erosion? Livedoid vasculopathy.
    Monroe JR
    JAAPA; 2012 May; 25(5):20. PubMed ID: 22712143
    [No Abstract]   [Full Text] [Related]  

  • 14. The management of livedoid vasculopathy focused on direct oral anticoagulants (DOACs): four case reports successfully treated with rivaroxaban.
    Franco Marques G; Criado PR; Alves Batista Morita TC; Cajas García MS
    Int J Dermatol; 2018 Jun; 57(6):732-741. PubMed ID: 29663354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Livedoid vasculopathy associated with peripheral neuropathy: a report of two cases.
    Tubone MQ; Escobar GF; Peruzzo J; Schestatsky P; Maldonado G
    An Bras Dermatol; 2013; 88(6 Suppl 1):227-9. PubMed ID: 24346927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Livedoid Vasculopathy With Rivaroxaban: A Potential Use of New Oral Anticoagulants for Dermatologists.
    Jiménez-Gallo D; Villegas-Romero I; Rodríguez-Mateos ME; Linares-Barrios M
    Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):278-281. PubMed ID: 29074145
    [No Abstract]   [Full Text] [Related]  

  • 17. Livedoid vasculopathy as a marker of systemic disease: report of two cases.
    Lima RS; Maquiné GÁ; Talhari C; Encarnação IC; Schettini AP; Santos M
    An Bras Dermatol; 2014; 89(5):822-4. PubMed ID: 25184928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of serum levels and cutaneous expression of lipoprotein (a) in 38 patients with livedoid vasculopathy.
    Espinel DPGS; Di Giacomo TB; Pincelli TP; Pereira NV; Sotto MN; Kirsner RS; Criado PR
    J Cutan Pathol; 2017 Dec; 44(12):1033-1037. PubMed ID: 28901563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Livedoid vasculopathy and recurrent thrombosis in a patient with lupus: seronegative antiphospholipid syndrome?
    Sopeña B; Pérez-Rodríguez MT; Rivera A; Ortiz-Rey JA; Lamas J; Freire-Dapena MC
    Lupus; 2010 Oct; 19(11):1340-3. PubMed ID: 20659971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Livedoid vasculopathy with underlying subcutaneous necrotizing venulitis in an asymptomatic hepatitis B virus carrier: is livedoid vasculopathy a true nonvasculitic disorder?
    Ishibashi M; Miyamoto J; Nagasaka T; Chen KR
    Am J Dermatopathol; 2009 May; 31(3):293-6. PubMed ID: 19384073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.